Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)a multicentre, double-blind, randomised, placebo-controlled trial
It particularly benefits those cells that are most metabolically active, such as those in heart muscles.* Although our body produces CoQ10, its production tends to decrease as we age
IB, Inhibitor of kappa B alpha
The GLP-1 agonists that are currently approved for weight loss are liraglutide (Saxenda) and semaglutide (Wegovy)
Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients